Cystic Fibrosis (CF) Exacerbation and Insulin Treatment

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate whether insulin treatment during pulmonary exacerbation (PE) in patients with Cystic Fibrosis (CF)and normoglycemia improves their short term outcome by normalizing the glycemic profile and enhancing recovery. the investigators would like to evaluate whether insulin treatment during exacerbation improves both the general clinical condition of these patients and also has a protecting effect on ß-cells by preventing the deleterious effect of "chronic" hyperglycemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hadassah Medical Organization
• Treatments: Insulin; Insulin Aspart; Insulin Lispro; Insulin, Globin Zinc; Insulin, Short-Acting

Criteria

Inclusion Criteria:

• Confirmed diagnosis of CF according to standard criteria

• Pancreatic insufficiency

• Age > 10 years

• Normal oral glucose tolerance test (OGTT) in the past 12 month.

• Acute pulmonary exacerbation (PE) according to the treating physician requires treatment with intravenous antibiotics

Exclusion Criteria:

• CF-related diabetes/impaired glucose tolerance test (IGTT) in a mixed meal tolerance test performed during full remission from pulmonary exacerbation